CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Gut bacteriophage dynamics during fecal microbial transplantation in subjects with metabolic syndrome
Authors
Willem M. de Vos
Hilde Herrema
+5 more
Pilar Manrique
Max Nieuwdorp
John van der Oost
Mark Young
Yifan Zhu
Publication date
1 January 2021
Publisher
Doi
Cite
Abstract
Publisher Copyright: © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.Metabolic Syndrome (MetS) is a growing public health concern worldwide. Individuals with MetS have an increased risk for cardiovascular (CV) disease and type 2 diabetes (T2D). These diseases–in part preventable with the treatment of MetS–increase the chances of premature death and pose a great economic burden to health systems. A healthy gut microbiota is associated with a reduction in MetS, T2D, and CV disease. Treatment of MetS with fecal microbiota transplantation (FMT) can be effective, however, its success rate is intermediate and difficult to predict. Because bacteriophages significantly affect the microbiota membership and function, the aim of this pilot study was to explore the dynamics of the gut bacteriophage community after FMT in MetS subjects. We performed a longitudinal study of stool bacteriophages from healthy donors and MetS subjects before and after FMT treatment. Subjects were assigned to either a control group (self-stool transplant, n = 3) or a treatment group (healthy-donor-stool transplant; n-recipients = 6, n-donors = 5). Stool samples were collected over an 18-week period and bacteriophage-like particles were purified and sequenced. We found that FMT from healthy donors significantly alters the gut bacteriophage community. Subjects with better clinical outcome clustered closer to the heathy donor group, suggesting that throughout the treatment, their bacteriophage community was more similar to healthy donors. Finally, we identified bacteriophage groups that could explain these differences and we examined their prevalence in individuals from a larger cohort of MetS FMT trial. Trial information- http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2705; NTR 2705.Peer reviewe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
NARCIS
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 29/05/2021
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 16/08/2021
Directory of Open Access Journals
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:doaj.org/article:5032348e1...
Last time updated on 04/09/2021
Helsingin yliopiston digitaalinen arkisto
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:helda.helsinki.fi:10138/33...
Last time updated on 21/12/2021
NARCIS
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 18/08/2021